Lates News

Zelboraf, jointly promoted by the Chinese biopharmaceutical company and Boehringer Ingelheim in mainland China, has been approved by the China National Medical Products Administration for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) in adult patients with HER2 (ERBB2) activating mutations who have previously received at least one systemic therapy. Zelboraf is the world's first and currently the only oral HER2 tyrosine kinase inhibitor. This conditional approval in China is based on the positive results of the Beamion-LUNG 1 study, which evaluated the efficacy and safety of Zelboraf in patients with HER2 (ERBB2) mutations in advanced NSCLC.